Cardiomyopathy

Cardiomyopathy

Introduction

Cardiomyopathy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Cardiomyopathy refers to a heterogeneous group of diseases of the heart muscle characterized by structural and functional abnormalities that impair the heart's ability to pump blood effectively. The condition encompasses several distinct entities with different etiologies, pathophysiology, and clinical outcomes. Beyond primary cardiac manifestations, emerging research has revealed important connections between certain cardiomyopathies and neurodegenerative disorders, particularly through shared mitochondrial dysfunction and genetic mechanisms. [@dissecting2019]

Overview

Cardiomyopathy affects approximately 1 in 500 individuals, with significant variation in prevalence across different subtypes and populations. The disease spectrum ranges from asymptomatic cases discovered incidentally to rapidly progressive heart failure requiring transplantation. The classification of cardiomyopathies has evolved to incorporate etiologic factors, with current schemes distinguishing between primary forms (genetic, acquired, or mixed) and secondary cardiomyopathies resulting from systemic conditions. [@ampkdependent]

Cardiomyopathy

Introduction

Cardiomyopathy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Cardiomyopathy refers to a heterogeneous group of diseases of the heart muscle characterized by structural and functional abnormalities that impair the heart's ability to pump blood effectively. The condition encompasses several distinct entities with different etiologies, pathophysiology, and clinical outcomes. Beyond primary cardiac manifestations, emerging research has revealed important connections between certain cardiomyopathies and neurodegenerative disorders, particularly through shared mitochondrial dysfunction and genetic mechanisms. [@dissecting2019]

Overview

Cardiomyopathy affects approximately 1 in 500 individuals, with significant variation in prevalence across different subtypes and populations. The disease spectrum ranges from asymptomatic cases discovered incidentally to rapidly progressive heart failure requiring transplantation. The classification of cardiomyopathies has evolved to incorporate etiologic factors, with current schemes distinguishing between primary forms (genetic, acquired, or mixed) and secondary cardiomyopathies resulting from systemic conditions. [@ampkdependent]

The connection between cardiomyopathy and neurodegeneration represents an emerging area of research interest. Several lines of evidence support bidirectional relationships: mitochondrial disorders commonly manifest with both cardiac and neurological involvement, while certain neurodegenerative diseases show increased rates of cardiac pathology. Understanding these connections has important implications for diagnosis, surveillance, and therapeutic approaches. [@lactococcus]

Classification and Types

Dilated Cardiomyopathy (DCM)

Dilated cardiomyopathy represents the most common form, characterized by progressive dilation and systolic dysfunction of the left ventricle: [@evaluation]

• Epidemiology: Prevalence of 1:2500, leading cause of heart transplantation
• Pathophysiology: Myocyte loss, chamber dilation, reduced ejection fraction
• Etiology: Genetic (over 50 genes), viral myocarditis, alcohol, chemotherapy
• Clinical features: Heart failure symptoms, arrhythmias, thromboembolism
• Treatment: Guideline-directed medical therapy, devices, transplantation

Hypertrophic Cardiomyopathy (HCM)

Hypertrophic cardiomyopathy features inappropriate ventricular hypertrophy, typically most prominent in the interventricular septum: [^6]

• Epidemiology: Prevalence of 1:500, most common genetic heart disease
• Pathophysiology: Myocyte disarray, fibrosis, diastolic dysfunction
• Etiology: Autosomal dominant mutations in sarcomere genes (MYH7, MYBPC3)
• Clinical features: Dyspnea, angina, syncope, sudden cardiac death risk
• Treatment: Beta-blockers, disopyramide, septal myectomy, alcohol ablation

Restrictive Cardiomyopathy

Restrictive cardiomyopathy is characterized by impaired ventricular filling with normal systolic function: [^7]

• Etiology: Amyloidosis, sarcoidosis, hemochromatosis, scleroderma
• Pathophysiology: Myocardial stiffening from infiltration or fibrosis
• Clinical features: Diastolic heart failure, preserved ejection fraction
• Treatment: Address underlying cause, diuretics, anticoagulation

Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

ARVC involves progressive replacement of ventricular myocardium with fibrofatty tissue: [^8]

• Epidemiology: Prevalence of 1:1000-5000
• Pathophysiology: Desmosomal mutations, cell death, fibrofatty replacement
• Clinical features: Ventricular arrhythmias, heart failure, sudden death
• Treatment: Antiarrhythmics, catheter ablation, ICD, transplantation

Left Ventricular Non-Compaction Cardiomyopathy (LVNC)

LVNC results from failed myocardial compaction during embryogenesis: [^9]

• Pathophysiology: Persisting embryonic trabecular pattern
• Clinical features: Heart failure, arrhythmias, thromboembolism
• Treatment: Standard heart failure therapy, anticoagulation

Genetics

Sarcomere Mutations

The majority of familial HCM results from mutations in sarcomeric protein genes: [^10]

| Gene | Protein | Frequency |
|------|---------|-----------|
| MYBPC3 | Myosin binding protein C | 40% |
| MYH7 | β-myosin heavy chain | 35% |
| TNNT2 | Troponin T | 5% |
| TNNI3 | Troponin I | 3% |
| MYL2/3 | Myosin light chains | 2% |

Mitochondrial Cardiomyopathy Genes

Mitochondrial DNA mutations and nuclear genes affecting mitochondrial function cause cardiomyopathy:

• MT-TL1, MT-ND: Mitochondrial tRNA and protein genes
• TAZ (Barth syndrome): Cardiolipin remodeling
• FRTXN: Iron-sulfur cluster assembly (Friedreich's ataxia)
• DMD: Dystrophin (Duchenne cardiomyopathy)

Desmosomal Genes (ARVC)

• PKP2, DSP, DSC2, JUP: Plakophilin, desmoplakin, desmoglein, plakoglobin

Neurodegeneration Connection

Mitochondrial Disorders

Mitochondrial diseases frequently involve both cardiac and neurological manifestations, representing the clearest link between cardiomyopathy and neurodegeneration:

MERRF (Myoclonic Epilepsy with Ragged Red Fibers)

• m.8344A>G mutation in MT-TL1
• Myoclonic epilepsy, myopathy, hearing loss
• Hypertrophic cardiomyopathy in 30-40% of cases
• Combined cardiac-neurological presentation

• m.3243A>G mutation in MT-TL1
• Encephalopathy, stroke, diabetes
• Cardiomyopathy in 20-30% of cases

• Large mitochondrial DNA deletions
• External ophthalmoplegia, cardiac conduction disease
• Cardiomyopathy develops in 20%

Friedreich's Ataxia

Friedreich's ataxia provides a paradigm for cardiomyopathy-neurodegeneration link:

• Genetic basis: GAA repeat expansion in FXN gene
• Frataxin deficiency: Impaired iron-sulfur cluster assembly
• Cardiac involvement: Hypertrophic cardiomyopathy in >90%
• Neurological features: Ataxia, dysarthria, sensory loss
• Pathophysiology: Mitochondrial iron overload, [ROS](/entities/reactive-oxygen-species), energy deficiency

Parkinson's Disease

Emerging evidence suggests bidirectional relationships:

• PD patients show increased cardiac denervation
• [Alpha-synuclein](/proteins/alpha-synuclein) deposits in cardiac tissue
• [LRRK2](/entities/lrrk2) mutations associated with cardiomyopathy
• Mitochondrial dysfunction common to both conditions

Huntington's Disease

Cardiac dysfunction in HD:

• Elevated cardiomyopathy risk
• Mutant [huntingtin](/proteins/huntingtin) affects cardiac gene expression
• Mitochondrial dysfunction in cardiac tissue

Diagnosis

Clinical Assessment

• Echocardiography: Chamber dimensions, function, wall thickness
• Cardiac MRI: Tissue characterization, fibrosis detection
• Electrocardiogram: Arrhythmias, conduction disease
• Endomyocardial biopsy: Rarely needed, for unclear etiologies

Genetic Testing

• Hypertrophic cardiomyopathy: Sarcomere gene panels
• Arrhythmogenic cardiomyopathy: Desmosome gene panels
• Mitochondrial disease: Mitochondrial and nuclear gene panels
• Family screening: Cascade testing when pathogenic variant identified

Treatment

Pharmacological Therapy

• Heart failure: ACE inhibitors, ARBs, ARNIs, beta-blockers, MRAs, SGLT2 inhibitors
• HCM: Beta-blockers, disopyramide, calcium channel blockers
• Arrhythmias: Antiarrhythmics, anticoagulation

Device Therapy

• Implantable cardioverter-defibrillator (ICD): Primary and secondary prevention
• Cardiac resynchronization therapy (CRT): For bundle branch block
• Pacemaker: Conduction disease management

Surgical Interventions

• Septal myectomy: For drug-refractory HCM
• Alcohol septal ablation: Alternative to surgery
• Heart transplantation: End-stage disease

Mitochondrial Cardiomyopathy-Specific Approaches

• Coenzyme Q10: Improves mitochondrial function in select cases
• L-carnitine: For carnitine deficiency
• Riboflavin: For complex I deficiency
• Idebenone: For Friedreich's ataxia cardiomyopathy

Prognosis

• Dilated cardiomyopathy: 5-year survival 50-80% with modern therapy
• Hypertrophic cardiomyopathy: Annual sudden death risk 1-2% with treatment
• Mitochondrial cardiomyopathy: Variable, depends on underlying mutation
• Heart transplantation: Excellent outcomes in selected patients

See Also

• [Mitochondrial Disorders](/diseases/mitochondrial-disorders)
• [Friedreich's Ataxia](/diseases/friedreichs-ataxia)
• [MELAS Syndrome](/diseases/melas-syndrome)
• [MERRF](/diseases/merrf)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Huntington's Disease](/diseases/huntingtons)

External Links

• [American Heart Association - Cardiomyopathy](https://www.heart.org/en/health-topics/cardiomyopathy)
• [Hypertrophic Cardiomyopathy Association](https://www.4hcm.org/)
• [Mitochondrial Disease Foundation](https://www.mitoaction.org/)

Background

The study of Cardiomyopathy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Invasion of gut-derived escherichia coli extracellular vesicles exacerbates myocardial ischemia/reperfusion injury.](https://pubmed.ncbi.nlm.nih.gov/41762624/) (2026 Dec 31) - Gut microbes
• [Dissecting burden of alcoholic cardiomyopathy: age-period-cohort analysis from the global burden of disease study 2019.](https://pubmed.ncbi.nlm.nih.gov/41736539/) (2026 Dec 31) - Clinical and experimental hypertension (New York, N.Y. : 1993)
• [AMPK-dependent maturation of hiPSC-derived cardiomyocytes induced by human cardiac fibroblast exosomes.](https://pubmed.ncbi.nlm.nih.gov/41703772/) (2026 Dec 31) - Clinical and experimental hypertension (New York, N.Y. : 1993)
• [Lactococcus lactis subsp. Cremoris reprograms systemic metabolism and protects against myocardial injury.](https://pubmed.ncbi.nlm.nih.gov/41486553/) (2026 Dec 31) - Gut microbes
• [Evaluation of ventricular dyssynchrony in fetuses of diabetic mothers measured by the tissue Doppler indices: a case-control study.](https://pubmed.ncbi.nlm.nih.gov/41819847/) (2026 Dec) - The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Cardiomyopathy discovered through SciDEX knowledge graph analysis: